16 patients ( 5 % ) in the TMP-SMX plus placebo group and 21 patients ( 7 % ) in the TMP-SMX plus doxycycline group developed culture-confirmed recurrent melioidosis ( HR 0.81 ; 95 % CI 0.42-1 .55 ) .